NP-01: Enhancing drug uptake in tumors
NP-01 encapsulates the chemotherapy drug doxorubicin in a light-activated nanoparticle to provide localized and systemic drug release.
NP-01 efficacy shown in preclinical mouse studies
Preclinical studies in mice show that NP-01 is effective in ablating tumors. These promising data highlight the great potential of NP-01 as an ablative cancer therapy. From: Biomaterials. 2016 January; 75: 193–202.
Cutaneous Metastatic Breast Cancer (CMBC)
41,000 women a year are diagnosed with skin metastases caused by stage IV breast cancer. This condition leads to painful lesions for which there is no effective treatment. With a clear medical need CMBC is an ideal first target for this novel nanomedicine.
C36: A Next Generation Vaccine Platform
A Next Generation Adjuvant for the Next Generation of Vaccines
C36 is similar to NP-01 but contains cobalt in its porphyrin ring structure, allowing it to easily conjugate with his-tagged peptides and proteins. This means that antigen-producing pharmaceutical companies can easily use C36 to particlize their antigens into a powerful vaccine candidate.
Powerful Antibody Response
When tested against typical adjuvants, the C36 advantage is clear. In trials with a malaria antigen, C36 was successful in blocking transmission of the disease. Future testing will continue to validate this up and coming vaccine platform.
Talented and passionate. Building a healthier future together.
Jonathan Lovell, PhD
Chief Scientific Officer
Jonathan is the co-inventor of the POP technologies. He's an assistant professor at the University at Buffalo and a winner of the NSF Career Award (2016).
Jonathan Smyth, JD
Chief Administrative Officer
Jonathan is a licensed NY attorney and has a strong passion for building businesses in Western New York.
Chief Operations Officer
Kevin is a Co-inventor of the POP technologies and a PhD student in the laboratory of Dr. Lovell.
Chris Choi, PhD, MBA
Chief Technical Officer
Chris is an assistant professor at Roswell Park Cancer Institute (RPCI) and the Director of the RPCI cGMP Therapeutic Cell Production facility.
Hilliard Kutscher, PhD
Hilliard is a research assistant professor at the University at Buffalo. He has a background in developing pharmaceutical formulations.
Chief Communications Officer
Henry is a MS student at the University at Buffalo. In addition, he's a project manager and the Lead Venture Coach at Blackstone Launchpad @ UB.